Policy brief: HTA on sildenafil as treatment for pulmonary arterial hypertension

07 September 2017

With support from ADP and other technical partners, Indonesia recently conducted HTA on sildenafil. This issue brief provides a summary of the evaluation that was implemented, which resulting in the finding that sildenafil is a more cost-effective treatment option for pulmonary arterial hypertension (PAH), compared to treatment currently used. Sildenafil was thus recommended to be included in the national health insurance benefit package.

Document group
Download link
Share on